Skip to main content

Research News

  • Hematopoietic Stem Cell Transplants May Provide Long-Term Benefit for People with MS

    A new study shows that intense immunosuppression followed by a hematopoietic stem cell transplant may prevent disability associated with multiple sclerosis (MS) from getting worse in 71% of people with relapsing-remitting MS for up to 10 years after the treatment. The research is published in the January 20, 2021, online issue of Neurology®, the medical journal of the American Academy of Neurology. The study also found that in some people their disability improved over 10 years after treatment.

  • Potential COVID-19 Drug Is Successful in Lab Study
    Potential COVID-19 Drug Is Successful in Lab Study

    A new potential therapy for COVID-19 developed by researchers at Rush University Medical Center has shown success in preventing the disease’s symptoms in mice.

  • Sunbathing after menopause may be harmful
    Sunbathing after menopause may be harmful

    UV-radiation can affect hormone levels of postmenopausal women negatively and this may contribute to several health issues.
    The concentration of oestrogens in the blood affects a woman’s health in many ways. For example, oestrogens contribute to a strong bone structure and help wounds heal more quickly.

    “When a woman reaches menopause, we see the levels of oestrogens decline and an increase of other hormones, called gonadotropins”, says Kai Triebner at the University of Bergen.

  • Nasal COVID-19 vaccine could soon be a reality
    Nasal COVID-19 vaccine could soon be a reality

    In a significant development, Bharat Biotech has sought Drug Controller General India's (DCGI) approval to conduct nasal COVID-19 vaccine trials in India. The company has developed a new single-dose nasal COVID-19 vaccine in a partnership with Washington University in St Louis, USA. There are no intra-nasal COVID-19 vaccines under trial in India at the moment.

  • How viruses escape the immune system
    How viruses escape the immune system

    One reason it’s so difficult to produce effective vaccines against some viruses, including influenza and HIV, is that these viruses mutate very rapidly. This allows them to evade the antibodies generated by a particular vaccine, through a process known as “viral escape.”

  • Taurine helps to prevent Bacterial Infection
    Taurine helps to prevent Bacterial Infection

    Scientists studying the body’s natural defenses against bacterial infection have identified a nutrient taurine that helps the gut recall prior infections and kill invading bacteria, such as Klebsiella pneumoniae (Kpn). The finding, published in the journal Cell by scientists from five institutes of the National Institutes of Health, could aid efforts seeking alternatives to antibiotics.

  • Novel coronavirus found in air samples : CCMB study
    Novel coronavirus found in air samples : CCMB study

    Airborne transmission of the novel coronavirus is possible under certain conditions, cautions a study undertaken by the Centre for Cellular and Molecular Biology (CCMB). The research was conducted to determine the transmission pattern of the virus in various enclosures in hospitals to assess the risks posed to healthcare workers. Air samples were collected from hospitals in Hyderabad and Mohali for the study.

  • New Class of Antibiotics Active Against a Wide Range of Bacteria : Reports
    New Class of Antibiotics Active Against a Wide Range of Bacteria : Reports

    Wistar Institute scientists have discovered a new class of compounds that uniquely combine direct antibiotic killing of pan drug-resistant bacterial pathogens with a simultaneous rapid immune response for combatting antimicrobial resistance (AMR).

  • Scientists reach new milestone in vaccine development for leishmaniasis
    Scientists reach new milestone in vaccine development for leishmaniasis

    Researchers have taken an important step forward in developing a controlled human infection model to test leishmaniasis vaccines.

    The University of York-led study identified and characterised a new strain of Leishmania parasite that will form the basis of a new controlled human infection model for the disease which is transmitted by the bite of sand flies. The team then produced the parasite to the standards required for use in human clinical studies.

  • COVAXIN vaccine shows remarkable immunogenicity and protective efficacy against SARS-CoV-2 (new coronavirus). It’s research name is BBV152 which an inactivated SARS-CoV-2 vaccine.

    Two doses vaccination regimen of inactivated SARS-CoV-2 vaccine candidates was administered in 20 rhesus macaques (divided into four groups equally). One group was administered with placebo, while three groups were immunized with 3 different vaccine candidates at 0 and 14 days. All the macaques were exposed to viral challenge 14 days after the 2nd dose. The results showed protective efficacy, increasing SARS-CoV-2 specific IgG and neutralizing antibodies, reducing replication of the virus in the nasal cavity, throat, and lung tissues of monkey.

    No evidence of pneumonia was observed by histopathological examination in vaccinated groups, unlike the placebo group. Adverse events were not seen in animals immunized with a two-dose vaccination regimen.

    Genomic RNA (gRNA) was detected from nasal swab (NS) specimens of all animals in the placebo group from 1 to 7 DPI (Days Post-Infection). Viral clearance was observed in NS specimens of all the animals from the vaccinated group on 7 DPI. Subgenomic RNA (sgRNA) was detected in two of five animals at 3 DPI and one of five animals at 7 DPI of the placebo group.  sgRNA was detected in the NS sample of only one animal of the vaccinated group IV on 5 DPI.

    Neutralizing antibodies and IgG responses were observed from 3rd-week post-immunization in vaccinated groups. IgG titer rose in an increasing pattern with the highest response in group III. The presence of gRNA in NS was observed in the placebo group until 7 DPI. Vaccinated groups had no detectable gRNA in NS on 7 DPI indicating the ability of vaccine candidates to limit upper respiratory tract viral replication, which is a key factor determining the virus transmission.


    gRNA and sgRNA were not detected in the Bronchoalveolar lavage fluid from 5 DPI suggesting that vaccination hindered virus replication and enabled faster clearance from lower airway protecting the animals. gRNA was detected in multiple organs at necropsy in the placebo group, whereas it was found to be cleared in the vaccinated groups.

    Altogether this study demonstrates that a two-dose vaccination regimen using 3µg dose of the vaccine candidate with adjuvant induce a significant immune response and provide effective protection in animals challenged with SARS-CoV-2.

    << Back to Pharma News

    Subscribe to PharmaTutor News Alerts by Email

Subscribe to Research News